<SUBMISSION>
<ACCESSION-NUMBER>0000950123-10-064430
<TYPE>SC 13D
<PUBLIC-DOCUMENT-COUNT>1
<FILING-DATE>20100708
<DATE-OF-FILING-DATE-CHANGE>20100708
<GROUP-MEMBERS>ARTISTRY ACQUISITION CORP.
<GROUP-MEMBERS>CELGENE CORPORATION
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D
<ACT>34
<FILE-NUMBER>005-83382
<FILM-NUMBER>10944925
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>CELGENE CORP /DE/
<CIK>0000816284
<ASSIGNED-SIC>2834
<IRS-NUMBER>222711928
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
<PHONE>(908)673-9000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<FILENAME>c03276sc13d.htm
<DESCRIPTION>SCHEDULE 13D
<TEXT>
<HTML>
<HEAD>
<TITLE>Schedule 13D</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid"> </DIV> <DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid"> </DIV> <P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>SCHEDULE 13D</B>


<P align="center" style="font-size: 12pt"><B>Under the Securities Exchange Act of 1934<BR>
(Amendment No.&nbsp;&nbsp;)*</B>


<DIV align="center">
<DIV style="font-size: 24pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">Abraxis BioScience, Inc.</DIV>
</DIV>


<DIV align="center" style="font-size: 10pt">(Name of Issuer)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">Common Stock, $0.001 par value per share</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(Title of Class of Securities)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">00383Y102</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(CUSIP Number)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">Maria Pasquale, Vice President and Chief Legal Counsel<BR>
Celgene Corporation<BR>
86 Morris Avenue<BR>
Summit, New Jersey 07901<BR>
Telephone: (908) 673-9000<BR><BR>
with a copy to:<BR><BR>
Jonn R. Beeson, Esq.<BR>
Kevin B. Espinola, Esq.<BR>
Jones Day<BR>
3161 Michelson Drive, Suite 800<BR>
Irvine, California  92612<BR>
Telephone:  (949) 851-3939</DIV>
</DIV>


<DIV align="center" style="font-size: 10pt">(Name, Address and Telephone Number of Person Authorized to<BR>
Receive Notices and Communications)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">June 30, 2010</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(Date of Event Which Requires Filing of this Statement)
</DIV>

<P align="left" style="font-size: 10pt">If the filing person has previously filed a statement on Schedule&nbsp;13G to report the acquisition that is the subject of this Schedule&nbsp;13D, and is filing this schedule because of &#167;&#167;240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. <FONT face="wingdings" size="2">&#111;</FONT>

<P align="left" style="font-size: 10pt"><B>Note: </B>Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

<P align="left" style="font-size: 10pt">* The remainder of this cover page shall be filled out for a reporting person&#146;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

<P align="left" style="font-size: 10pt">The information required on the remainder of this cover page shall not be deemed to be &#147;filed&#148; for the purpose of Section 18 of the Securities Exchange Act of 1934 (&#147;Act&#148;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt">
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;<DIV style="width: 100%; border: 1px solid black"><DIV align="center">

<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="1" width="100%">
<!-- Begin Table Head --><TR style="font-size: 1px">
<TD width="5%">&nbsp;</TD>
<TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="83%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD valign="middle" align="center"><FONT style="font-size: 18pt"><B>1</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">NAMES OF REPORTING PERSONS<BR>
<BR>
Celgene Corporation</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>2</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<BR><BR></TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(a)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#111;</FONT>&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(b)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#254;</FONT>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>3</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SEC USE ONLY</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>4</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SOURCE OF FUNDS (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">Not applicable</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>5</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>6</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CITIZENSHIP OR PLACE OF ORGANIZATION</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Delaware
</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>7</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">NUMBER OF</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">SHARES</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>8</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">BENEFICIALLY</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">OWNED BY</TD>
<TD>&nbsp;</TD>
<TD>33,215,612 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>


<TR valign="bottom">
<TD align="center" colspan="3">EACH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>9</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">REPORTING</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">PERSON</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>
<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">WITH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>10</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>11</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">33,215,612 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>12</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF THE AGGREGATE AMOUNT IN ROW (11)&nbsp;EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT>
</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>13</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">82.1&#37;(2)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>14</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CO</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">(1) Comprised of (i) 33,186,067 issued and outstanding
shares of common stock, par value $0.001 per share (the &#147;Shares&#148;) of Abraxis BioScience, Inc.
(&#147;Abraxis&#148;) owned by the Committed Stockholders (as defined in Item 3 below) and (ii)
vested options owned by the Committed Stockholders to purchase 29,545 Shares (which, upon issuance,
will become New Shares as defined in the Voting Agreement described in Item 4 below), which may be
deemed to be beneficially owned by Celgene Corporation pursuant to the Voting Agreement.
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">(2) The calculation of this percentage is based on 40,403,163
Shares issued and outstanding as of June 25, 2010, as represented by Abraxis in the Merger Agreement described
in Item 4 below.
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>


<P align="center" style="font-size: 10pt">

2

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;<DIV style="width: 100%; border: 1px solid black"><DIV align="center">

<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="1" width="100%">
<!-- Begin Table Head --><TR style="font-size: 1px">
<TD width="5%">&nbsp;</TD>
<TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="83%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD valign="middle" align="center"><FONT style="font-size: 18pt"><B>1</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">NAMES OF REPORTING PERSONS<BR>
<BR>
Artistry Acquisition Corp.</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>2</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<BR><BR></TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(a)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#111;</FONT>&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(b)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#254;</FONT>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>3</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SEC USE ONLY</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>4</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SOURCE OF FUNDS (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">Not applicable</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>5</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>6</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CITIZENSHIP OR PLACE OF ORGANIZATION</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Delaware
</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>7</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">NUMBER OF</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">SHARES</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>8</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">BENEFICIALLY</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">OWNED BY</TD>
<TD>&nbsp;</TD>
<TD>33,215,612 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>


<TR valign="bottom">
<TD align="center" colspan="3">EACH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>9</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">REPORTING</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">PERSON</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>
<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">WITH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>10</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>11</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">33,215,612 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>12</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF THE AGGREGATE AMOUNT IN ROW (11)&nbsp;EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT>
</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>13</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">82.1&#37;(2)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>14</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CO</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">(1) Comprised of (i) 33,186,067 issued and outstanding Shares owned
by the Committed Stockholders and (ii) vested options owned by the Committed Stockholders to purchase 29,545 Shares
(which, upon issuance, will become New Shares as defined in the Voting Agreement), which may be deemed to be beneficially
owned by Artistry Acquisition Corp. pursuant to the Voting Agreement.
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">(2) The calculation of this percentage is based on 40,403,163 Shares
issued and outstanding as of June 25, 2010, as represented by Abraxis in the Merger Agreement described in Item 4 below.
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>


<P align="center" style="font-size: 10pt">

3

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Security and Issuer</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This statement on Schedule&nbsp;13D (this &#147;Schedule&nbsp;13D&#148;) relates to shares of common stock, par
value $0.001 per share (the &#147;Shares&#148;), of Abraxis BioScience, Inc., a Delaware corporation
(&#147;Abraxis&#148;), whose principal executive offices are located at 11755 Wilshire Boulevard, Suite&nbsp;2000,
Los Angeles, CA 90025.
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Identity and Background</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;&#151; (c)&nbsp;and (f)&nbsp;The persons filing this Schedule&nbsp;13D are Celgene Corporation, a Delaware
corporation (&#147;Parent&#148;), and Artistry Acquisition Corp., a Delaware corporation (&#147;Merger Sub&#148;). The
principal executive offices of each of Parent and Merger Sub are located at 86 Morris Avenue,
Summit, New Jersey 07901. The telephone number for each of Parent and Merger Sub is (908)&nbsp;673-9000.
Parent&#146;s principal business is the discovery, development and commercialization of innovative
therapies designed to treat cancer and immune-inflammatory related diseases. Merger Sub is a
newly-formed subsidiary of Parent, organized to effect the Merger (as defined below). Merger Sub
has not conducted, and does not expect to conduct, any business other than in connection with the
Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The name, citizenship, business address, present principal occupation or employment (and the
name, principal business and address of any corporation or other organization in which such
employment is conducted) for each director and executive officer of Parent and Merger Sub are set
forth in Annex I hereto and incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(d)&nbsp;&#151; (e)&nbsp;During the last five years, none of Parent or Merger Sub or, to the knowledge of
Parent or Merger Sub, any of the persons listed on Annex I attached hereto, has (i)&nbsp;been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii)&nbsp;been a
party to any judicial or administrative proceeding that resulted in a judgment, decree or final
order enjoining any of them from future violations of, or prohibiting activities subject to, U.S.
federal or state securities laws, or a finding of any violation of U.S. federal or state securities
laws.
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;3.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Source and Amount of Funds or Other Consideration</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As more fully described in response to Item&nbsp;4, the Shares to which this Schedule&nbsp;13D relates
have not been purchased by Parent or Merger Sub. As an inducement to Parent and Merger Sub
entering into the Merger Agreement described in Item&nbsp;4, and in consideration thereof, certain of
Abraxis&#146; stockholders (each a &#147;Committed Stockholder&#148; and collectively, the &#147;Committed
Stockholders&#148;) entered into a Voting Agreement, dated as of June&nbsp;30, 2010 (the &#147;Voting Agreement&#148;),
pursuant to which each Committed Stockholder has agreed, among other things, to vote its respective
Shares in favor of, or execute consents in favor of, the approval and adoption of the Merger
Agreement and the transactions contemplated by the Merger Agreement, at any meeting of, or in
connection with any proposed action by written consent of, the holders of Shares, on the terms and
subject to the conditions set forth in the Voting Agreement. Neither Parent nor Merger Sub paid
additional consideration to the Committed Stockholders in connection with the execution and
delivery of the Voting Agreement. For a description of the Voting Agreement, see Item&nbsp;4 below,
which description is incorporated herein by reference. Any beneficial ownership of Parent and
Merger Sub in Abraxis that may be deemed to arise from the Voting Agreement is not expected to
require the expenditure of any funds. See Item&nbsp;4 for a description of the Merger Agreement and the
merger consideration to be paid thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">References to, and descriptions of, the Merger Agreement and the Voting Agreement as set forth
herein are not intended to be complete and are qualified in their entirety by reference to the
Merger Agreement and the Voting Agreement, respectively, copies of which are filed as Exhibit&nbsp;1 and
Exhibit&nbsp;3, respectively, to this Schedule&nbsp;13D and which are incorporated by reference in this Item
3 in their entirety.
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Purpose of Transaction</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent, Merger Sub and the Committed Stockholders entered into the Voting Agreement as an
inducement to Parent&#146;s and Merger Sub&#146;s willingness to enter into the Merger Agreement. The
purpose of the Merger Agreement is to acquire control of, and the entire equity interest in,
Abraxis. The purpose of the Voting Agreement is to facilitate the transactions contemplated by the
Merger Agreement.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Merger Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On the terms and subject to the conditions of the Merger Agreement, at the Effective Time,
each Share issued and outstanding immediately prior to the Effective Time (other than treasury
Shares of Abraxis and any Shares owned by Parent, Merger Sub or any wholly owned subsidiary of
Parent or Abraxis, and any Dissenting Company Shares (as defined in the Merger Agreement)) will be
converted into the right to receive (i)&nbsp;an amount in cash, without interest, equal to $58.00 (the
&#147;Cash Consideration&#148;), (ii)&nbsp;0.2617 (the &#147;Exchange Ratio&#148;) of a share of common stock, par value
$.01 per share, of Parent (the &#147;Parent Common Stock&#148;), and (iii)&nbsp;one contingent value right issued
by Parent subject to and in accordance with the CVR Agreement described below (collectively, the
&#147;Merger Consideration&#148;). No fractional shares of Parent Common Stock will be issued in the Merger,
and Abraxis stockholders will receive cash in lieu of fractional shares, if any, of Parent Common
Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All outstanding stock options (&#147;Options&#148;), stock appreciation rights (&#147;SARs&#148;) and restricted
stock units (&#147;RSUs&#148;) of Abraxis will be canceled at the Effective Time. Holders of Options and
SARs with an exercise or base price below the Per Share Amount (as defined below) will receive, for
each Share subject to such Option or SAR, (i)&nbsp;a cash payment equal to the difference between the
Per Share Amount and the exercise price or base price of the Option or SAR, as applicable, and (ii)
one CVR. Holders of Options and SARs with an exercise or base price above the Per Share Amount
will be given the right to elect, during a period of at least five business days ending the
business day preceding the closing of the Merger, to pay to Abraxis a cash payment equal to the
difference between the exercise price or base price of the Option or SAR, as applicable, and the
Per Share Amount, and in exchange receive one CVR. Holders of RSUs will receive (i)&nbsp;a cash payment
equal to the Per Share Amount and (ii)&nbsp;one CVR. The &#147;Per Share Amount&#148; means the sum of (x)&nbsp;the
amount obtained by multiplying (1)&nbsp;the Exchange Ratio and (2)&nbsp;the Parent Share Cash Value (as
defined below), with such amount rounded up to the nearest cent, and (y)&nbsp;the Cash Consideration.
The &#147;Parent Share Cash Value&#148; will be an amount equal to the average of the closing sale prices for
Parent Common Stock on the NASDAQ, as reported in The Wall Street Journal, for each of the ten
consecutive trading days ending with the seventh complete trading day prior to the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent and Abraxis each made representations, warranties and covenants in the Merger
Agreement, including, among others, covenants by Abraxis to conduct its business in the ordinary
course during the interim period between the execution of the Merger Agreement and consummation of
the Merger. The representations and warranties contained in the Merger Agreement are made for the
purposes of allocation of risk between the parties and as conditions to closing, may be subject to
exceptions in a disclosure letter provided before the signing of the Merger Agreement, are not
necessarily accurate or complete as made and should not be relied upon by any stockholders or
potential investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Merger Agreement prohibits Abraxis from soliciting or knowingly encouraging competing
acquisition proposals. However, Abraxis may, subject to the terms and conditions set forth in the
Merger Agreement, provide information to a third party that makes an unsolicited acquisition
proposal, and may engage in discussions and negotiations with a third party that makes an
unsolicited acquisition proposal that the Abraxis board of directors determines constitutes or is
reasonably likely to result in a Superior Proposal (as defined in the Merger Agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The consummation of the Merger is subject to customary closing conditions, including the
approval of Abraxis&#146; stockholders and the expiration or termination of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act and the effectiveness of Parent&#146;s Registration
Statement on Form S-4 covering shares of Parent Common Stock and CVRs to be issued in the Merger,
and the approval of such shares of Parent Common Stock for listing (subject to notice of issuance)
on NASDAQ.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Merger Agreement also provides for certain termination rights for both Parent and Abraxis.
Upon termination of the Merger Agreement under specified circumstances, Abraxis may be required to
pay Parent a termination fee of $145&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Merger Agreement provides that, at the Effective Time, Merger Sub will be merged with and
into Abraxis, with Abraxis continuing as the surviving corporation (the &#147;Surviving Corporation&#148;).
The amended and restated certificate of incorporation of Abraxis, as in effect immediately prior to
the Effective Time, will, by virtue of the Merger, be amended and restated in a form mutually
agreed and, as so amended, will be the certificate of incorporation of the Surviving Corporation,
until changed or amended in accordance with its terms and as provided by applicable law and the
Merger Agreement. The by-laws of Merger Sub, in effect immediately prior to the
Effective Time, will be the by-laws of the Surviving Corporation, until changed or amended in
accordance with their terms and as provided by applicable law and the Merger Agreement.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The directors of Merger Sub and the officers of Abraxis in office immediately prior to the
Effective Time will be the directors and officers, respectively, of the Surviving Corporation, in
each case until their respective successors have been duly elected or appointed and qualified or
until their earlier death, resignation or removal, in accordance with the Surviving Corporation&#146;s
certificate of incorporation and by-laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent and Merger Sub currently expect that the registration of the Shares under the Exchange
Act and the listing of the Shares on the NASDAQ will be terminated upon completion of the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Contingent Value Rights Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">At the closing of the Merger, Parent and a mutually acceptable trustee will enter into a
Contingent Value Rights Agreement (&#147;CVR Agreement&#148;) governing the terms of the CVRs. A holder of a
CVR is entitled to receive a pro rata portion of cash payments that Parent is obligated to pay to
all holders of CVRs, as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Net Sales Payments</I>. For each full one-year period ending December&nbsp;31 during the
term of the CVR Agreement (a &#147;Net Sales Measuring Period&#148;), a payment that equals (i)
2.5% of that portion of Net Sales of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and the other Products (as each such
term is defined in the CVR Agreement) that exceeds $1&nbsp;billion but is less than or equal
to $2&nbsp;billion for such period, plus (ii)&nbsp;an additional amount equal to 5.0% of that
portion of Net Sales of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and the other Products that exceeds $2&nbsp;billion but is
less than or equal to $3&nbsp;billion for such period, plus (iii)&nbsp;an additional amount equal
to 10.0% of that portion of Net Sales of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and the other Products that exceeds
$3&nbsp;billion for such period; provided that no Net Sales Payments will be due following a
Net Sales Payment Termination Date. &#147;Net Sales Payment Termination Date&#148; is defined as
the last day of the Net Sales Measuring Period ending on December&nbsp;31, 2025; provided
that, if Net Sales of the Products for the Net Sales Measuring Period ending on
December&nbsp;31, 2025 are equal to or greater than $1&nbsp;billion , then the Net Sales Payment
Termination Date will be extended until the earlier of (x)&nbsp;the last day of the Net
Sales Measuring Period during which Net Sales of the Products are less than $1&nbsp;billion
and (y)&nbsp;December&nbsp;31, 2030.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Milestone Payment #1</I>. $250&nbsp;million, with respect to the achievement of U.S.
regulatory approval of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for use in the treatment of non-small cell lung
cancer, which permits Parent to market such Product under a label that includes a
progression free survival claim, but only if the foregoing milestone is achieved no
later than the fifth anniversary of the execution of the CVR Agreement.</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Milestone Payment #2</I>. $400&nbsp;million (if achieved no later than April&nbsp;1, 2013) or
$300&nbsp;million (if achieved after April&nbsp;1, 2013 and before the fifth anniversary of the
CVR Agreement), with respect to the achievement of U.S. regulatory approval of
Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for use in the treatment of pancreatic cancer, which permits Parent to market
such Product under a label that includes an overall survival claim.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent has agreed to use diligent efforts to achieve each of the Milestones above through the
fifth year anniversary of the CVR Agreement and to use diligent efforts to obtain FDA regulatory
approval for the commercial manufacture, marketing and sale of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for the treatment of
melanoma, ovarian cancer, bladder cancer and first-line metastatic breast cancer unless the data
generated in an appropriate clinical trial does not support further development of Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> for
the applicable indication. Parent has also agreed to use diligent efforts to sell Abraxane<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> or any
other Products for which Parent has obtained regulatory approval for the commercial manufacture,
marketing and sale thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent has agreed to use its reasonable best efforts to cause the CVRs to be approved for
listing for trading on NASDAQ and to maintain such listing for as long as CVRs remain outstanding.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Parent may, at any time on and after the date that fifty percent of the CVRs initially issued
pursuant to the terms of the Merger Agreement either are (i)&nbsp;no longer outstanding, and/or (ii)
repurchased, acquired, redeemed or retired by Parent, redeem all (but not less than all) of the
outstanding CVRs at a cash redemption price equal to the average price paid for all CVRs by Parent
in prior transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Voting Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As an inducement to Parent and Merger Sub and as a condition to Parent and Merger Sub entering
into the Merger Agreement, concurrently with the execution of the Merger Agreement, Dr.&nbsp;Patrick
Soon-Shiong and related entities holding, in the aggregate, approximately 82% of the issued and
outstanding Shares (the &#147;Committed Stockholders&#148;) entered in a Voting Agreement with Parent and
Merger Sub (the &#147;Voting Agreement&#148;), pursuant to which the Committed Stockholders have agreed,
subject to the terms thereof, to vote their Shares in favor of, or execute consents in favor of,
the approval and adoption of the Merger Agreement and the transactions contemplated thereby, and
against, among other things, any business combination or extraordinary corporate transaction other
than the Merger or another business combination or transaction with Parent or any of its
affiliates, at any meeting of, or in connection with any proposed action by written consent of, the
holders of Shares. The Committed Stockholders also granted Parent an irrevocable proxy to vote
their Shares in accordance with the preceding sentence.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Voting Agreement also limits the ability of the Committed Stockholders to sell or
otherwise transfer their Shares, other than to certain permitted transferees. The Voting Agreement
will terminate upon the earlier to occur of (i)&nbsp;the Effective Time, (ii)&nbsp;a material amendment of
the Merger Agreement that is adverse to the Committed Stockholders that is not consented to by the
Committed Stockholders (including a decrease or change in the form of the Merger Consideration) and
(iii)&nbsp;the termination of the Merger Agreement in accordance with its terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Non-Competition, Non-Solicitation and Confidentiality Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">As an inducement to Parent and as a condition to Parent entering into the Merger Agreement,
concurrently with the execution of the Merger Agreement, Dr.&nbsp;Patrick Soon-Shiong entered in a
Non-Competition, Non-Solicitation and Confidentiality Agreement with Parent (the &#147;Noncompetition
Agreement&#148;), pursuant to which, among other things, Dr.&nbsp;Soon-Shiong will be generally prohibited,
for 10&nbsp;years from and after the Effective Time, subject to certain exceptions, from owning or
otherwise engaging in the business of researching, developing, licensing, manufacturing, selling,
offering for sale, importing, using, marketing, distributing, practicing or otherwise exploiting
any Albumin-Bound Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Products (as defined in the Noncompetition Agreement) in the United States
and any foreign jurisdiction in which Abraxis was engaged in the business of researching,
developing, licensing, manufacturing, selling, offering for sale, importing, using, marketing,
distributing, practicing or otherwise exploiting any Albumin-Bound Nab<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Products as of the
Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Stockholders&#146; Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Concurrently with the execution of the Merger Agreement, certain of the Committed Stockholders
entered in a Stockholders&#146; Agreement with Parent (the &#147;Stockholders&#146; Agreement&#148;), pursuant to
which, among other things, the Committed Stockholders have agreed not to sell, pledge or otherwise
transfer the Parent Common Stock to be acquired by them in the Merger (the &#147;Merger Common Stock&#148;)
for three years following the Effective Time, other than to certain permitted transferees or in
connection with a third party tender or exchange offer, merger or similar transaction involving
Parent; provided that after two years the Committed Stockholders may sell up to 25% of the
aggregate Merger Common Stock held by all Committed Stockholders immediately after the Effective
Time. In addition, the Committed Stockholders have agreed that prior to the fourth anniversary of
the Merger, the Committed Stockholders will not sell, pledge or otherwise transfer, in any calendar
month, in open market transactions, more than 30% of the aggregate Merger Common Stock held by all
Committed Stockholders immediately after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Other than as described in this Item&nbsp;4, Parent and Merger Sub have no present plans or
proposals that would relate to or result in any of the matters listed in paragraphs (a)&nbsp;through (j)
of Item&nbsp;4 of Schedule&nbsp;13D (although Parent and Merger Sub reserve the right to formulate specific
plans and proposals with respect to, or
change their intentions regarding, any or all of the foregoing, subject to the terms of the Merger
Agreement and the Voting Agreement).
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The information set forth, or incorporated by reference, in Items 3, 5 and 6 of this Schedule
13D is hereby incorporated by this reference in this Item&nbsp;4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">References to, and descriptions of, the Merger Agreement, the CVR Agreement, the Voting
Agreement, the Noncompetition Agreement and the Stockholders&#146; Agreement as set forth herein are not
intended to be complete and are qualified in their entirety by reference to the Merger Agreement,
the CVR Agreement, the Voting Agreement, the Noncompetition Agreement and the Stockholders&#146;
Agreement, respectively, copies of which are filed as Exhibit&nbsp;1, Exhibit&nbsp;2, Exhibit&nbsp;3, Exhibit&nbsp;4
and Exhibit&nbsp;5, respectively, to this Schedule&nbsp;13D and which are incorporated by reference in this
Item&nbsp;4 in their entirety.
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Interest in Securities of the Issuer</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;&#151; (b)&nbsp;For the purpose of Rule&nbsp;13d-3 under the Exchange Act, Parent and Merger Sub, by
reason of the execution and delivery of the Voting Agreement, may be deemed to have shared voting
power with the Committed Stockholders with respect to (and therefore beneficially own within the
meaning of Rule&nbsp;13d-3 under the Exchange Act) an aggregate of 33,215,612 Shares, comprised of (i)
33,186,067 issued and outstanding Shares owned by the Committed Stockholders and (ii)&nbsp;vested
options owned by the Committed Stockholders to purchase 29,545 Shares (which, upon issuance, will
become New Shares as defined in the Voting Agreement), representing approximately 82% of Abraxis&#146;
issued and outstanding Shares (assuming 40,403,163 Shares issued and outstanding as of June&nbsp;25,
2010, as represented by Abraxis in the Merger Agreement). With respect to the voting of the
Shares, Parent (or its designee) has the power to vote or direct the voting of the Shares in
accordance with the terms of the Voting Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Except as set forth in this Item&nbsp;5, none of Parent or Merger Sub or, to the knowledge of
Parent or Merger Sub, any of the persons listed on Annex I attached hereto, beneficially owns or
has the power to vote or cause the vote of any Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Neither the filing of this Schedule&nbsp;13D nor any of its contents shall be deemed to constitute
an admission that Parent or Merger Sub is the beneficial owner of the Shares subject to the Voting
Agreement for purposes of Section 13(d) of the Exchange Act or for any other purpose, and such
beneficial ownership is expressly disclaimed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(c)&nbsp;Except for the execution and delivery of the Voting Agreement and the Merger Agreement,
no transactions in Shares were effected by Parent, Merger Sub or, to the knowledge of Parent or
Merger Sub, any of the persons listed on Annex I attached hereto, during the 60&nbsp;days prior to the
date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(d)&nbsp;&#151; (e)&nbsp;Not applicable.
</DIV>

<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;6.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the
Issuer</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The information set forth, or incorporated by reference, in Items 3 through 5 of this Schedule
13D is hereby incorporated by reference in this Item&nbsp;6. Except as otherwise described in this
Schedule&nbsp;13D, to the knowledge of Parent and Merger Sub, there are no contracts, arrangements,
understandings or relationships (legal or otherwise) among the persons named in Item&nbsp;2 above, and
between any such persons and any other person, with respect to any securities of Abraxis.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="7%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;7.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Material to be Filed as Exhibits</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement and Plan of Merger, dated as of June&nbsp;30, 2010, by and among Parent, Merger Sub and
Abraxis (incorporated by reference to Exhibit&nbsp;2.1 to the Current Report on Form 8-K filed by
Parent on July&nbsp;1, 2010).</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Form of Contingent Value Rights Agreement (incorporated by reference to Exhibit&nbsp;10.1 to the
Current Report on Form 8-K filed by Parent on July&nbsp;1, 2010).</TD>
</TR>


</TABLE>
</DIV>



<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Voting Agreement, dated as of June&nbsp;30, 2010, by and among Parent, Merger Sub, Dr.&nbsp;Patrick
Soon-Shiong, California Capital LP, Patrick Soon-Shiong 2009 GRAT 1, Patrick Soon-Shiong 2009
GRAT 2, Michele B.
Soon-Shiong GRAT 1, Michele B. Soon-Shiong GRAT 2, Soon-Shiong Community Property Revocable
Trust, The Chan Soon-Shiong Family Foundation, California Capital Trust and Michele B. Chan
Soon-Shiong (incorporated by reference to Exhibit&nbsp;10.2 to the Current Report on Form 8-K filed
by Parent on July 1 2010).</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Non-Competition, Non-Solicitation and Confidentiality Agreement, dated as of June&nbsp;30, 2010,
by and between Parent and Dr.&nbsp;Patrick Soon-Shiong (incorporated by reference to Exhibit&nbsp;10.3
to the Current Report on Form 8-K filed by Parent on July&nbsp;1, 2010).</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Stockholders&#146; Agreement, dated as of June&nbsp;30, 2010, by and among Parent, Dr.&nbsp;Patrick
Soon-Shiong, California Capital LP, Patrick Soon-Shiong 2009 GRAT 1, Patrick Soon-Shiong 2009
GRAT 2, Michele B. Chan Soon-Shiong GRAT 1, Michele B. Chan Soon-Shiong GRAT 2, Soon-Shiong
Community Property Revocable Trust, California Capital Trust and Michele B. Chan Soon-Shiong
(incorporated by reference to Exhibit&nbsp;10.4 to the Current Report on Form 8-K filed by Parent
on July&nbsp;1, 2010)</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Celgene Corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David W. Gryska
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David W. Gryska&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President and<br>
Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Artistry Acquisition Corp.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Andre Van Hoek
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Andre Van Hoek&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: July&nbsp;8, 2010
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ANNEX I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 10pt"><B>Information Concerning Directors and Executive Officers of Celgene Corporation</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table sets forth the name, present principal occupation or employment, and
material occupations, positions, offices or employment for at least the past five years of each
director and executive officer of Celgene Corporation. Unless otherwise indicated, all positions
set forth below opposite an individual&#146;s name refer to positions within Celgene. The current
business address of each of these individuals is 86 Morris Avenue, Summit, New Jersey 07901, and
the current business phone number of each of these individuals is (908)&nbsp;673-9000. Each of the
persons listed below is a U.S. citizen.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U><B>Board of Directors</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sol J. Barer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">After the annual meeting of Celgene&#146;s stockholders on
June&nbsp;16, 2010, Dr.&nbsp;Barer transitioned from Chief
Executive Officer to Executive Chairman of the Board
of Directors, a position he will hold until December
31, 2010. Prior to that, Dr.&nbsp;Barer served as
Celgene&#146;s Chief Executive Officer since May&nbsp;1, 2006.
Dr.&nbsp;Barer also served as Celgene&#146;s President from
October&nbsp;1993 to May&nbsp;1, 2006 and as Celgene&#146;s Chief
Operating Officer from March&nbsp;1994 to May&nbsp;1, 2006. Dr.
Barer has served as the Chairman of the Board of
Directors since January&nbsp;2, 2007 and, since March
1994, has served as a director of Celgene. He is also
the Chairman of the Executive Committee of the Board
of Directors. Dr.&nbsp;Barer was Senior Vice
President&#151;Science and Technology and Vice
President/General Manager&#151;Chiral Products from
October&nbsp;1990 to October&nbsp;1993 and Celgene&#146;s Vice
President&#151;Technology from September&nbsp;1987 to October
1990. Dr.&nbsp;Barer received a Ph.D. in organic chemistry
from Rutgers University. Dr.&nbsp;Barer is also a director
of Amicus Therapeutics and serves on the Board of
Trustees of BioNJ and the Board of the Brooklyn
College Foundation. Dr.&nbsp;Barer previously served as
Commissioner of the New Jersey Commission on Science
and Technology.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert J. Hugin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">After the annual meeting of Celgene&#146;s stockholders on
June&nbsp;16, 2010, Mr.&nbsp;Hugin became Celgene&#146;s new Chief
Executive Officer. Prior to that, Mr.&nbsp;Hugin served
as Celgene&#146;s Chief Operating Officer and President
since May&nbsp;1, 2006. He also served as Celgene&#146;s Senior
Vice President and Chief Financial Officer from June
1999 until May&nbsp;1, 2006. Mr.&nbsp;Hugin has served as a
director of Celgene since December&nbsp;2001. Previously,
Mr.&nbsp;Hugin had been a Managing Director at J.P. Morgan
&#038; Co. Inc., which he joined in 1985. Mr.&nbsp;Hugin
received an A.B. degree from Princeton University and
an M.B.A. from the University of Virginia. Mr.&nbsp;Hugin
is also a director of The Medicines Company, Atlantic
Health System, Inc., a non-profit health care system,
and Family Promise, a national non-profit network
assisting homeless families.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">




<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Michael D. Casey
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Casey has served as a director of Celgene since
August&nbsp;2002, is Chairman of the Nominating Committee
and a member of the Executive Committee (since
December&nbsp;2006) and the Management Compensation and
Development Committee (since April&nbsp;2006) of the Board
of Directors. He became Celgene&#146;s lead independent
director in June&nbsp;2007. Mr.&nbsp;Casey was a member of the
Audit Committee from August&nbsp;2002 through December
2006. From September&nbsp;1997 to February&nbsp;2002, Mr.&nbsp;Casey
served as the Chairman, President, Chief Executive
Officer and a director of Matrix Pharmaceutical, Inc.
From November&nbsp;1995 to September&nbsp;1997, Mr.&nbsp;Casey was
Executive Vice President at Schein Pharmaceutical,
Inc. In December&nbsp;1996, he was
appointed President of
the retail and specialty products division of Schein
Pharmaceutical. From June&nbsp;1993 to November&nbsp;1995, he
served as President and Chief Operating Officer of
Genetic Therapy, Inc. Mr.&nbsp;Casey was President of
McNeil Pharmaceutical (a unit of Johnson &#038; Johnson)
from 1989 to June&nbsp;1993 and Vice President, Sales and
Marketing for Ortho Pharmaceutical Corp. (a
subsidiary of Johnson &#038; Johnson) from 1985 to 1989.
Mr.&nbsp;Casey is also a director of Durect Corp. and AVI
BioPharma, and served as director of Allos
Therapeutics, Inc. through January&nbsp;2010.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Carrie S. Cox
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ms. Cox was elected to the Board of Directors of
Celgene effective December&nbsp;16, 2009 and is a member
of the Audit Committee (since March&nbsp;2010). Ms.&nbsp;Cox
served as Executive Vice President and President of
Schering-Plough&#146;s Global Pharmaceutical Business
until November&nbsp;3, 2009 when Schering-Plough merged
with Merck &#038; Co., Inc. Prior to joining
Schering-Plough, Ms.&nbsp;Cox served as President of
Pharmacia Corporation&#146;s pharmaceutical business until
its merger with Pfizer Inc. in 2003. Ms.&nbsp;Cox is a
member of the Board of Directors of Texas Instruments
and has served on their audit and compensation
committees, and has recently been appointed to the
Board of Directors of Cardinal Health, Inc. Ms.&nbsp;Cox
is also a member of the Harvard School of Public
Health&#146;s Health Policy and Management Executive
Council and a member of the Board of Overseers of the
University of Pennsylvania Museum of Archaeology and
Anthropology. Ms.&nbsp;Cox is a graduate of the
Massachusetts College of Pharmacy.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rodman L. Drake
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Drake has served as a director of Celgene since
April&nbsp;2006, is Chairman of the Compensation Committee
since June&nbsp;2007 and a member of the Nominating
Committee of the Board of Directors. Since January
2002, Mr.&nbsp;Drake has been Managing Director of Baringo
Capital LLC, a private equity group he co-founded.
From November&nbsp;1997 to January&nbsp;2002, Mr.&nbsp;Drake was
president of Continuation Investments Group Inc., a
private equity firm. Prior to that, Mr.&nbsp;Drake was
co-chairman of the KMR Power Company and Chief
Executive Officer and Managing Director of Cresap
McCormick and Paget, a leading management consulting
firm, and served as President of the Mandrake Group,
a consulting firm specializing in strategy and
organizational design. He is a member of the boards
of directors of The Student Loan Corporation, Jackson
Hewitt Tax Service, Inc., Crystal River Capital, Inc.
and The Animal Medical Center of New York. He is the
Chairman of the Helios Funds and a Trustee of the
Columbia Atlantic Funds. From 2007 to 2009, Mr.&nbsp;Drake
served as a member of the board of directors of
Golden Minerals Company, formerly Apex Silver Mines
Limited.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gilla Kaplan, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dr. Kaplan has served as a director of Celgene since
April&nbsp;1998 and is a member of the Audit Committee of
the Board of Directors. Dr.&nbsp;Kaplan is head of the
Laboratory of Mycobacterial Immunity and Pathogenesis
at The Public Health Research Institute Center at the
University of Medicine and Dentistry of New Jersey in
Newark, New Jersey, where she was appointed full
Member in 2002. Dr.&nbsp;Kaplan also was appointed, in
2005, Professor of Medicine at the University of
Medicine and Dentistry of New Jersey. Previously, Dr.
Kaplan was an immunologist in the Laboratory at
Cellular Physiology and Immunology at The Rockefeller
University in New York where she was an Associate
Professor.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James J. Loughlin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Loughlin has served as a director of Celgene
since January&nbsp;2007, is Chairman of the Audit
Committee (since June&nbsp;2008) and a member of the
Compensation Committee (since June&nbsp;2008) of the Board
of Directors. Mr.&nbsp;Loughlin served as the National
Director of the Pharmaceuticals Practice at
KPMG LLP,
including a five-year term as member of the Board of
Directors of KPMG. Additionally, Mr.&nbsp;Loughlin served
as Chairman of the Pension and Investment Committee
of the KPMG Board from 1995 through 2001. He also
served as Partner in charge of Human Resources,
Chairman of the Personnel and Professional
Development Committee, Secretary and Trustee of the
Peat Marwick Foundation and a member of the Pension,
Operating and Strategic Planning Committees. In
addition, Mr.&nbsp;Loughlin served as a member of the
Boards of Directors of Alfacell Corporation (until
2008) and Datascope Corp. (until January&nbsp;2009).</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ernest Mario, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dr. Mario has served as a director of Celgene since
August&nbsp;2007 and is a member of the Nominating
Committee (since August&nbsp;2007) and the Executive
Committee (since June&nbsp;2008) of the Board of
Directors. Dr.&nbsp;Mario is a former Deputy Chairman and
Chief Executive of Glaxo Holdings plc and a former
Chairman and Chief Executive Officer of ALZA
Corporation. Dr.&nbsp;Mario has been a Director of Boston
Scientific since October&nbsp;2001 and currently is the
Lead Director of Pharmaceutical Product Development.
From 2003 to 2007, he was Chairman and Chief
Executive of Reliant Pharmaceuticals. Dr.&nbsp;Mario
currently is the Chief Executive Officer and Chairman
of Capnia, Inc., a privately held specialty
pharmaceutical company in Palo Alto, CA. A former
Trustee of Duke University, he serves on the Board of
the Duke University Health System. He is Chairman of
the American Foundation for Pharmaceutical Education
and serves as an advisor to the pharmacy schools at
the University of Rhode Island and The Ernest Mario
School of Pharmacy at Rutgers University. Dr.&nbsp;Mario
is the recipient of the 2007 Remington Honor Medal,
which is the highest recognition given by the
American Pharmacists Association.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Walter L. Robb, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Robb has served as a director of Celgene since
1992 and is a member of the Audit Committee of the
Board of Directors. He has been a private consultant
and President of Vantage Management Inc., a
consulting and investor services company, since
January&nbsp;1993. Dr.&nbsp;Robb was Senior Vice President for
Corporate Research and Development of General
Electric Company, and a member of its Corporate
Executive Council from 1986 to December&nbsp;1992. Dr.
Robb is Chairman of the Board of Directors of Capital
District Sports. He also is a director of Mechanical
Technology, Inc., a public company, and several
private companies.</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><U><B>Executive Officers</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sol J. Barer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">See information provided above.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert J. Hugin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">See information provided above.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">David W. Gryska
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">David W. Gryska has served as Celgene&#146;s Senior
Vice President and Chief Financial Officer since
joining the company in December of 2006. Prior
to joining Celgene, he was a principal at
Strategic Consulting Group, where he was
responsible for investing and providing
strategic consulting to earlier-stage
biotechnology companies. From 1998 to 2004, he
was Senior Vice President and Chief Financial
Officer at SCIOS, Inc. From 1993 to 1998, he
served as Vice President and Chief Financial
Officer of Cardiac Pathways, a company later
acquired by Boston Scientific Corporation. Prior
to Cardiac Pathways, Mr.&nbsp;Gryska spent eleven
years at Ernst &#038; Young. He holds a B.A. in
accounting and finance from Loyola University
and an M.B.A. from Golden Gate University. Mr.
Gryska also serves as a member of the board of
directors of Seattle Genetics.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Aart Brouwer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Brouwer has served as Chairman International
and Senior Advisor to Celgene&#146;s Chairman and
Chief Executive Officer since January&nbsp;1, 2009.
He joined Celgene in November&nbsp;2005.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Graham Burton, MBBS, FRCP
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Burton has served as Senior Vice President
Global Regulatory Affairs, Pharmacovigilance,
Corporate Quality and Compliance since July&nbsp;1,
2003. He joined Celgene in July&nbsp;2003.</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Information Concerning Directors and Executive Officers of Artistry Acquisition Corp.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table sets forth the name, present principal occupation or employment, and
material occupations, positions, offices or employment for at least the past five years of each
director and executive officer of Artistry Acquisition Corp. Unless otherwise indicated, all
positions set forth below opposite an individual&#146;s name refer to positions within Artistry
Acquisition Corp. The current business address of each of these individuals is 86 Morris Avenue,
Summit, New Jersey 07901, and the current business phone number of each of these individuals is
(908)&nbsp;673-9000. Each of the persons listed below is a U.S. citizen.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Andre Van Hoek
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Hoek has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010 and serves as its President.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sandesh Mahatme
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Mahatme has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010 and serves as its Treasurer and
Secretary.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Wayne Folkart
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Folkart has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010.</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
